⚠ Novel chemotype — no close known analogue (best Tanimoto < 0.3). Unexplored chemical space relative to ChEMBL.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13160144 | 0.71 | — | — | |
| SCHEMBL23169946 | 0.71 | — | — | |
| SCHEMBL27529682 | 0.71 | — | — | |
| SCHEMBL9068665 | 0.71 | — | — | |
| SCHEMBL790311 | 0.71 | — | — | |
| SCHEMBL18510170 | 0.67 | — | — | |
| SCHEMBL20411614 | 0.67 | — | — | |
| SCHEMBL10875964 | 0.67 | — | — | |
| SCHEMBL8839223 | 0.67 | — | — | |
| SCHEMBL4397 | 0.67 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 292 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230051589-A1 | COMPOUNDS AND COMPOSITIONS FOR TREATING CONDITIONS ASSOCIATED WITH NLRP ACTIVITY | NOVARTIS AG (CH) | 2023-02-16 | — | — | US | claimed |
| EP-3880659-A1 | COMPOUNDS AND COMPOSITIONS FOR TREATING CONDITIONS ASSOCIATED WITH NLRP ACTIVITY | Novartis AG (CH) | 2021-09-22 | — | — | EP | claimed |
| CN-113416229-A | Cytotoxic and antimitotic compounds, and methods of use thereof | 酵活有限公司 | 2021-09-21 | — | — | CN | claimed |
| CN-113286784-A | Compounds and compositions for treating conditions associated with NLRP activity | 诺华股份有限公司 | 2021-08-20 | — | — | CN | claimed |
| US-20200207865-A2 | CYTOTOXIC AND ANTI-MITOTIC COMPOUNDS, AND METHODS OF USING THE SAME | ZYMEWORKS BC INC. (CA) | 2020-07-02 | — | — | US | claimed |
| WO-2020102576-A1 | COMPOUNDS AND COMPOSITIONS FOR TREATING CONDITIONS ASSOCIATED WITH NLRP ACTIVITY | NOVARTIS INFLAMMASOME RESEARCH, INC. (US) | 2020-05-22 | — | — | WO | claimed |
| US-20190345254-A1 | CYTOTOXIC AND ANTI-MITOTIC COMPOUNDS, AND METHODS OF USING THE SAME | ZYMEWORKS INC (CA) | 2019-11-14 | — | — | US | claimed |
| US-10414822-B2 | Cytotoxic and anti-mitotic compounds, and methods of using the same | ZYMEWORKS INC. (CA) | 2019-09-17 | — | — | US | claimed |
| US-20180208667-A1 | CYTOTOXIC AND ANTI-MITOTIC COMPOUNDS, AND METHODS OF USING THE SAME | ZYMEWORKS BC INC. (CA) | 2018-07-26 | — | — | US | claimed |
| US-9879086-B2 | Cytotoxic and anti-mitotic compounds, and methods of using the same | ZYMEWORKS INC. (CA) | 2018-01-30 | — | — | US | claimed |
| US-20020173501-A1 | Antimicrobial quinolones, their compositions and uses | THE PROCTER & GAMBLE COMPANY | 2002-11-21 | — | — | US | claimed |
| WO-2002048143-A2 | ANTIMICROBIAL 2-PYRIDONES, THEIR COMPOSITIONS AND USES | THE PROCTER & GAMBLE COMPANY (US) | 2002-06-20 | — | — | WO | claimed |
| US-6387928-B1 | BACTERICIDES; SIDE EFFECT REDUCTION | THE PROCTER & GAMBLE CO. | 2002-05-14 | — | — | US | claimed |
| US-20020049192-A1 | Antimicrobial quinolones, their compositions and uses | THE PROCTER & GAMBLE COMPANY | 2002-04-25 | — | — | US | claimed |
| US-6329391-B1 | ANTIBIOTICS, BACTERICIDES USING QUINOLONES | THE PROCTER & GAMBLE CO. | 2001-12-11 | — | — | US | claimed |
| JP-2001516756-A | — | — | 2001-10-02 | — | — | JP | claimed |
| CN-1278813-A | Antimicrobial quinolones, their compositions and uses | PROCTER & GAMBLE (US) | 2001-01-03 | — | — | CN | claimed |
| EP-1015445-A1 | ANTIMICROBIAL QUINOLONES, THEIR COMPOSITIONS AND USES | THE PROCTER & GAMBLE COMPANY (US) | 2000-07-05 | — | — | EP | claimed |
| WO-1999014214-A1 | ANTIMICROBIAL QUINOLONES, THEIR COMPOSITIONS AND USES | THE PROCTER & GAMBLE COMPANY (US) | 1999-03-25 | — | — | WO | claimed |
| EP-0188110-B1 | Hydrogel-forming polymers | TR DEV LTD (GB) | 1995-09-06 | — | — | EP | claimed |